#hptx

New Post has been published on http://www.stockmarketsdaily.com/downgrade-prospects-hyperion-therapeutics-inc-nasdaqhptx/12534/

Downgrade Prospects: Hyperion Therapeutics Inc (NASDAQ:HPTX)

(adsbygoogle = window.adsbygoogle || []).push();

Hyperion Therapeutics, Inc. (NASDAQ:HPTX) has been downgraded by 2 brokers in the last 2 days from buy to holds. With that in mind we have a look at what other brokers on the Street think of Hyperions prospects.  [Trend Analysis]

Analysis

Hyperion Therapeutics, Inc. (NASDAQ:HPTX) last traded at $45.90 after moving down -0.17% for the trading day. The company last released their quarterly earnings results on Feb 26th for the period ended Dec-14. The company reported earnings of $0.37 against a Zack’s research estimate of -$0.13. This represents a 384.62% surprise on the expected result.

The current average broker recommendation for Hyperion Therapeutics, Inc., according to Zack’s research, is 1.67, based on 6 broker ratings. With 1 being a strong buy and 5 being a strong sell, this means that on a consensus basis, analysts currently see Hyperion Therapeutics, Inc. as a buy. The 12 month target consensus price estimate among these analysts for Hyperion Therapeutics, Inc. is currently at $43.00.

Out of the 6 broker recommendations for HPTX, 4 recommend it as a strong buy, 0 as a buy, 2 as a hold 0 as a sell and 0 as a strong sell.

For the current quarter, the consensus analyst estimate for Hyperion Therapeutics, Inc. (NASDAQ:HPTX) is $0.17, with analysts expecting year on year growth for the company of 37.50%

About Hyperion Therapeutics, Inc. (NASDAQ:HPTX)